Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Nivolumab has shown durable response and safety in patients with hepatocellular carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients, especially those with Child–Pugh class B, are limited. To investigate the effectiveness and safety of nivolumab in a real-world c...

Full description

Bibliographic Details
Main Authors: Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Changhoon Yoo, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Jonggi Choi
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
liver cancer
immune checkpoint inhibitor
effectiveness
safety
Online Access:https://www.mdpi.com/2072-6694/12/7/1968

Similar Items

Similar Items